| 000 | 01780 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517143959.0 | ||
| 264 | 0 | _c20180319 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1747-4132 | ||
| 024 | 7 |
_a10.1080/17474124.2017.1309284 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFlisiak, Robert | |
| 245 | 0 | 0 |
_aOmbitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. _h[electronic resource] |
| 260 |
_bExpert review of gastroenterology & hepatology _cJun 2017 |
||
| 300 |
_a559-567 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _a2-Naphthylamine |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAnilides _xadministration & dosage |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCarbamates _xadministration & dosage |
| 650 | 0 | 4 | _aCyclopropanes |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLactams, Macrocyclic |
| 650 | 0 | 4 |
_aMacrocyclic Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aProline _xanalogs & derivatives |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 |
_aSulfonamides _xadverse effects |
| 650 | 0 | 4 | _aSustained Virologic Response |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUracil _xadverse effects |
| 650 | 0 | 4 | _aValine |
| 700 | 1 | _aFlisiak-Jackiewicz, Marta | |
| 773 | 0 |
_tExpert review of gastroenterology & hepatology _gvol. 11 _gno. 6 _gp. 559-567 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/17474124.2017.1309284 _zAvailable from publisher's website |
| 999 |
_c26991470 _d26991470 |
||